OncoC4 key facts
as of Oct 2026- Operator of a biopharmaceutical company intended for the discovery of novel biologicals for cancer and neurodegenerative disease treatments.
- OncoC4 is valued at approximately $660.0M as of Oct 2026 (last reported valuation).
- It has raised $50.0M; the latest was Later Stage VC ($50.0M) in Sep 2025.
- Notable investors include National Institutes of Health, 3E Bioventures Capital, Greater Bay Area Homeland, Kaitai Capital.
- OncoC4 has filed 1 Form D with the SEC, most recently Jan 2021 ( sold to 1 investors).
- Status: Privately Held (backing).
OncoC4's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·Watch OncoC4: the Monday email on marks, rounds and moves
OncoC4 funding rounds
No funding rounds for OncoC4 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
OncoC4 valuation
OncoC4's last reported valuation was $660 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
How much has OncoC4 raised?
OncoC4 has filed 1 Form D with the SEC, most recently in Jan 2021 (null sold to 1 investor).
OncoC4 investors
4 investors are on record for OncoC4, including National Institutes of Health, 3E Bioventures Capital, Greater Bay Area Homeland and Kaitai Capital.
About OncoC4
Operator of a biopharmaceutical company intended for the discovery of novel biologicals for cancer and neurodegenerative disease treatments. The company develops immunotherapy products targeting cancer evasion of adaptive and innate immunity, enabling healthcare providers to avail drugs that uncouple therapeutic effects and immunotherapy-related adverse effects.
- Sector
- Healthcare
- HQ
- Rockville, MD, United States
- Founded
- 2020
- Employees
- 70
- Website
- oncoc4.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.